Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

R. Dummer, KT. Flaherty, C. Robert, A. Arance, JWB. de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, D. Schadendorf, N. Yamazaki, A. di Pietro, J. Cantey-Kiser, M. Edwards, PA. Ascierto

. 2022 ; 40 (36) : 4178-4188. [pub] 20220721

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032131

PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453). METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned. RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard. CONCLUSION: In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032131
003      
CZ-PrNML
005      
20230131151126.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.21.02659 $2 doi
035    __
$a (PubMed)35862871
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dummer, Reinhard $u University Hospital Zurich, Zurich, Switzerland $1 https://orcid.org/0000000222796906
245    10
$a COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma / $c R. Dummer, KT. Flaherty, C. Robert, A. Arance, JWB. de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, D. Schadendorf, N. Yamazaki, A. di Pietro, J. Cantey-Kiser, M. Edwards, PA. Ascierto
520    9_
$a PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453). METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned. RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard. CONCLUSION: In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma.
650    _2
$a lidé $7 D006801
650    _2
$a vemurafenib $x terapeutické užití $7 D000077484
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a mutace $7 D009154
650    12
$a melanom $x farmakoterapie $x genetika $7 D008545
650    _2
$a laktátdehydrogenasy $7 D045022
650    12
$a nádory kůže $x farmakoterapie $x genetika $7 D012878
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Flaherty, Keith T $u Massachusetts General Hospital, Boston, MA $1 https://orcid.org/0000000234020478
700    1_
$a Robert, Caroline $u Gustave Roussy and Paris-Saclay University, Villejuif, France $1 https://orcid.org/0000000294930238
700    1_
$a Arance, Ana $u Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain $1 https://orcid.org/0000000328961957
700    1_
$a de Groot, Jan Willem B $u Isala Oncology Center, Zwolle, the Netherlands
700    1_
$a Garbe, Claus $u University Hospital Tubingen, Tubingen, Germany $1 https://orcid.org/000000018530780X
700    1_
$a Gogas, Helen J $u National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000204512885
700    1_
$a Gutzmer, Ralf $u Hannover Medical School, Hannover, and Ruhr-University Bochum, Minden Campus, Germany $1 https://orcid.org/0000000179212820
700    1_
$a Krajsová, Ivana $u University Hospital Prague, Prague, Czech Republic
700    1_
$a Liszkay, Gabriella $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Loquai, Carmen $u University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Mandalà, Mario $u University of Perugia, Perugia, Italy $1 https://orcid.org/0000000188468959
700    1_
$a Schadendorf, Dirk $u University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany $1 https://orcid.org/0000000335247858
700    1_
$a Yamazaki, Naoya $u National Cancer Center Hospital, Tokyo, Japan $1 https://orcid.org/0000000296380428
700    1_
$a di Pietro, Alessandra $u Pfizer, Milan, Italy
700    1_
$a Cantey-Kiser, Jean $u PharPoint Research, Durham, NC
700    1_
$a Edwards, Michelle $u Pfizer, New York, NY
700    1_
$a Ascierto, Paolo A $u Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy $1 https://orcid.org/000000028322475X
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 40, č. 36 (2022), s. 4178-4188
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35862871 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151122 $b ABA008
999    __
$a ok $b bmc $g 1891104 $s 1183466
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 40 $c 36 $d 4178-4188 $e 20220721 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace